Healthcare Industry News: dual anti-platelet therapy
News Release - April 20, 2010
OrbusNeich Announces Full Availability of Genous(TM) Bio-engineered Cobalt Chromium Stent Following CE Mark ApprovalCompany's patented endothelial progenitor cell (EPC) capture technology now available on thinner, flexible stent
HONG KONG, April 20 -- (Healthcare Sales & Marketing Network) -- OrbusNeich announced that following CE Mark (Conformite Europeenne) approval, its Genous Bio-engineered Cobalt Chromium Stent is now commercially available.
The Genous Bio-engineered Cobalt Chromium Stent combines OrbusNeich's patented endothelial progenitor cell (EPC) capture technology, Genous, with a L605 cobalt chromium bare metal stent based on the company's proven Blazer™ stent design. The thin cobalt chromium stent struts exhibit a low profile and great flexibility for ideal deliverability, while the dual helix stent design provides superior radial strength and excellent sidebranchability for effective bifurcation stenting. The combination of the Genous technology with the new platform provides physicians with a stent designed to modulate restenosis and protect against thrombosis.
"The cobalt chromium Genous stent will allow us to use its superior mechanical properties to provide further treatment options in tortuous, complex or distal coronary disease, especially in those patients in whom prolonged dual anti-platelet therapy is undesirable," said Dr. Smith from Morriston Hospital, Swansea, Wales, United Kingdom.
Al Novak, OrbusNeich's Chairman and CEO, added, "OrbusNeich is excited to offer the effective and proven EPC capture technology on a thin cobalt chromium stent. Interventional cardiologists now have more choices to treat challenging patient groups, such as diabetic patients, with a safe and effective alternative to drug-eluting stents."
Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that accelerates the natural healing process of the vessel wall after stent implantation. The technology consists of an antibody surface coating that captures EPCs circulating in the blood, which form a functional endothelial layer that provides protection against thrombosis and modulates restenosis.
OrbusNeich's Genous Bio-engineered R stent™ has been commercially available in over 60 countries since 2005. The Genous stent has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 6,000 patients in clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.
OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Bio-engineered R stent, as well as stents, balloons and guiding catheters marketed under the names of Blazer™, R stent, Scoreflex™, Sapphire™, Sapphire NC, and Lumina™. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan.. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.